Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Butyrate-producing bacteria are a polyphyletic group of primarily anaerobic, Gram-positive gut commensals that metabolize dietary fiber and resistant starches to produce butyrate, a short-chain fatty acid vital for colonic health. Genera include Faecalibacterium, Roseburia, Eubacterium, Clostridium, Coprococcus, Anaerostipes, and others. Butyrate produced by these microbes is the preferred energy source for colonic epithelial cells, helps maintain mucosal integrity, and exhibits anti-inflammatory and anti-cancer effects. Alteration in the abundance or activity of these bacteria has been linked to inflammatory, metabolic, infectious, and neurodegenerative diseases. They are not conventional molecular targets or receptors, but are studied as live biotherapeutics and essential components of a healthy gut microbiome
Probiotics: Colonization and increased butyrate/SCFA production Engineered strains: Enhanced fermentation pathways to boost butyrate output Butyrate acts on host: Activation of G-protein coupled SCFA receptors (e.g., GPR43/FFAR2, GPR41/FFAR3, GPR109A), inhibition of histone deacetylases, modulation of immune and epithelial cell function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Butyrate-producing bacterium.